Evidence map›Paper›PMID 37692340›Full record

ArticleRSC advances2023

Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer.

Jingjing Zhou, Lina Ma, Zhenshengnan Li, Bowen Chen, Yue Wu, Xianying Meng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jingjing ZhouThyroid Surgery Department, General Surgery Center, First Hosipital of Jilin University Changchun 130021 P. R. China mengxiany@jlu.edu.cn.
Lina MaCollege of Traditional Chinese Medicine, Jilin Agricultural Science and Technology College Jilin 132101 P. R. China.
Zhenshengnan LiThyroid Surgery Department, General Surgery Center, First Hosipital of Jilin University Changchun 130021 P. R. China mengxiany@jlu.edu.cn.
Bowen ChenThyroid Surgery Department, General Surgery Center, First Hosipital of Jilin University Changchun 130021 P. R. China mengxiany@jlu.edu.cn.
Yue WuThyroid Surgery Department, General Surgery Center, First Hosipital of Jilin University Changchun 130021 P. R. China mengxiany@jlu.edu.cn.
Xianying MengThyroid Surgery Department, General Surgery Center, First Hosipital of Jilin University Changchun 130021 P. R. China mengxiany@jlu.edu.cn.
Jilin University · CNFirst Hospital of Jilin University · CNChangchun Institute of Applied Chemistry · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC) is the most malignant and aggressive of all classifications of thyroid cancer. ATC normally has poor prognosis after classic treatments such as surgery, endocrine therapy, radiotherapy and chemotherapy. Herein, a novel nanocomposite (named as UCNP@PDA@LEN) has been synthesized for chemo-photothermal therapy of ATC, which is based on a NaErF

Identifiers

PMID37692340
PMCPMC10483932
OpenAlexW4386527431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.